NOTE TO READERS: When this project lost substantial funding at the end of 2018, I lost the ability to continue publishing criteria-driven news story reviews and PR news release reviews - once the bread-and-butter of the site going back to 2006. The 3,200 archived reviews, while still educational, are getting old and difficult for me to technically maintain on the back end of the website. So I am announcing that I plan to remove these reviews from the site by April 1, 2021. The blog and the toolkit - two of the most popular features on the site - will remain. If you wish to peruse the reviews before they disappear, please do so by the end of March 2021. After that date you may still be able to access them via the Internet Archive Wayback Machine - https://archive.org/web/.
Read Original Story

Study: One dose of radiation during breast cancer surgery is effective

Rating

3 Star

Study: One dose of radiation during breast cancer surgery is effective

Our Review Summary

This story reports on a large, randomized trial comparing conventional radiation therapy for breast cancer administered over several weeks to a one-time dose given at the time of breast conserving surgery. The study found that both treatments resulted in similar rates of breast cancer recurrence. The story does a nice job of describing the study and adding the appropriate caveats. For example, the writer makes it clear that the single-dose regimen may require subsequent conventional radiation therapy, as pathology results are not always available at the time of surgery. This story would have been vastly improved had it included data from the trial, mentioned costs, given more detail on associated harms, pointed out potential conflicts of interest, and adequately compared the single-dose radiation therapy to other accelerated radiation therapy regimens.

 

Why This Matters

The inconvenience of conventional radiation therapy delivered over several weeks can be a real barrier for many women, particularly women who continue to work through treatment or those who are older and find it difficult to make every session. The story could have been easily oversold, but the writer maintained an appropriately cautious tone.   

Criteria

Does the story adequately discuss the costs of the intervention?

Not Satisfactory

There was no discussion of costs, nor of the cost ramifications of the results. 

 

Does the story adequately quantify the benefits of the treatment/test/product/procedure?

Satisfactory

The story indicated that the local breast cancer recurrence rate was the same for those who received conventional, external radiation and those who received intraoperative radiation; however, no data were provided.

While it was good that they noted that “[i]t’s best for women with a small tumor that is well-defined and involves only one portion of the breast,” it would have been much more meaningful had they defined “small” and included more details on the criteria for selection, as not all breast cancer patients meet the eligibility criteria for this treatment.

Does the story adequately explain/quantify the harms of the intervention?

Not Satisfactory

The story pointed out the potential disadvantages of this treatment, including that many patients (14%) who receive targeted intraoperative radiation therapy still require conventional radiation.

While the rate of major toxicities were, indeed, similar between those who received targeted intraoperative therapy and those who received conventional radiation, it would have been helpful to note that significantly more people in the intraoperative therapy group had wound seromas needing more than three aspirations. The story may have also noted that the conventional therapy was associated with a higher toxicity grade compared to the one-time therapy.

Does the story seem to grasp the quality of the evidence?

Satisfactory

This story did a nice job of describing some important details of the study: the number of patients, their diagnosis, randomization, and the length of follow-up. 

Does the story commit disease-mongering?

Satisfactory

The story did not engage in disease mongering.

Does the story use independent sources and identify conflicts of interest?

Not Satisfactory

The story provided quotes from independent sources, but it failed to mention that the study authors received funding and consulting fees from Carl Zeiss, the manufacturer of the equipment used in this study. We think such disclosure should be part of any story – and it only requires a few more words.

Does the story compare the new approach with existing alternatives?

Not Satisfactory

While the focus of the study was to compare conventional radiation therapy to one-time intraoperative radiation, more than just a cursory mention of other accelerated regimens would have been useful. For example, MammoSite is administered for 5 days and is also delivered from inside the breast. Additionally, studies have demonstrated that a traditional external radiation administered over 3 weeks is as effective as the 7-week regimen for some patients.

Does the story establish the availability of the treatment/test/product/procedure?

Satisfactory

The story makes it clear that this is a new treatment approach and has not yet been established as an available option. 

Does the story establish the true novelty of the approach?

Satisfactory

While accelerated regimens of radiation therapy are gaining traction, the story makes it clear that delivering one dose of radiation during surgery is a novel treatment approach. 

Does the story appear to rely solely or largely on a news release?

Satisfactory

This story does not appear to be based on the press release.

 

Total Score: 6 of 10 Satisfactory

Comments

Please note, comments are no longer published through this website. All previously made comments are still archived and available for viewing through select posts.